1. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease. (March 2022) Authors: Srivastava, Shashikant; Pasipanodya, Jotam G.; Heysell, Scott K.; Boorgula, Gunavanthi D.; Gumbo, Tawanda; McShane, Pamela J.; Philley, Julie V. Journal: Journal of global antimicrobial resistance Issue: Volume 28(2022) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria. (December 2022) Authors: Shankar, Prem; Singh, Sanjay; Boorgula, Gunavanthi D.; Gumbo, Tawanda; Heysell, Scott K.; Srivastava, Shashikant Journal: Tuberculosis Issue: Volume 137(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!. (28th November 2018) Authors: Srivastava, Shashikant; Deshpande, Devyani; Magombedze, Gesham; Gumbo, Tawanda Journal: Clinical infectious diseases Issue: Volume 67(2018)Supplement 3 Page Start: S359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. (28th November 2018) Authors: Deshpande, Devyani; Pasipanodya, Jotam G; Mpagama, Stellah G; Srivastava, Shashikant; Bendet, Paula; Koeuth, Thearith; Lee, Pooi S; Heysell, Scott K; Gumbo, Tawanda Journal: Clinical infectious diseases Issue: Volume 67(2018)Supplement 3 Page Start: S317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children. Issue 12 (December 2020) Authors: Srivastava, Shashikant; van Zyl, Johanna; Cirrincione, Kayle; Martin, Katherine; Thomas, Tania; Deshpande, Devyani; Alffenaar, Jan-William; Seddon, James A.; Gumbo, Tawanda Journal: Pediatric infectious disease journal Issue: Volume 39:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis. (3rd February 2015) Authors: Pasipanodya, Jotam; Srivastava, Shashikant; Gumbo, Tawanda Journal: Journal of infectious diseases Issue: Volume 212:Number 1(2015:Jul. 01) Page Start: 166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Gatifloxacin Pharmacokinetics/Pharmacodynamics–based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. (28th November 2018) Authors: Deshpande, Devyani; Pasipanodya, Jotam G; Srivastava, Shashikant; Bendet, Paula; Koeuth, Thearith; Bhavnani, Sujata M; Ambrose, Paul G; Smythe, Wynand; McIlleron, Helen; Thwaites, Guy; Gumusboga, Mourad; Van Deun, Armand; Gumbo, Tawanda Journal: Clinical infectious diseases Issue: Volume 67(2018)Supplement 3 Page Start: S274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. (16th February 2023) Authors: Gumbo, Tawanda; Srivastava, Shashikant; Deshpande, Devyani; Pasipanodya, Jotam G; Berg, Alexander; Romero, Klaus; Hermann, David; Hanna, Debra Journal: Journal of antimicrobial chemotherapy Issue: Volume 78:Number 4(2023) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. (9th December 2016) Authors: Vinnard, Christopher; Ravimohan, Shruthi; Tamuhla, Neo; Ivaturi, Vijay; Pasipanodya, Jotam; Srivastava, Shashikant; Modongo, Chawangwa; Zetola, Nicola M.; Weissman, Drew; Gumbo, Tawanda; Bisson, Gregory P. Journal: British journal of clinical pharmacology Issue: Volume 83:Number 4(2017:Apr.) Page Start: 801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii. (January 2023) Authors: Boorgula, Gunavanthi D.; Singh, Sanjay; Shankar, Prem; Gumbo, Tawanda; Heysell, Scott K.; Srivastava, Shashikant Journal: Tuberculosis Issue: Volume 138(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗